KR102826491B1 - Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 - Google Patents

Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 Download PDF

Info

Publication number
KR102826491B1
KR102826491B1 KR1020217009936A KR20217009936A KR102826491B1 KR 102826491 B1 KR102826491 B1 KR 102826491B1 KR 1020217009936 A KR1020217009936 A KR 1020217009936A KR 20217009936 A KR20217009936 A KR 20217009936A KR 102826491 B1 KR102826491 B1 KR 102826491B1
Authority
KR
South Korea
Prior art keywords
compound
lung
pharmaceutically acceptable
mmol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217009936A
Other languages
English (en)
Korean (ko)
Other versions
KR20210056381A (ko
Inventor
다니엘 디. 롱
카메론 스미스
코빈 톰슨
Original Assignee
세라밴스 바이오파마 알앤디 아이피, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 filed Critical 세라밴스 바이오파마 알앤디 아이피, 엘엘씨
Publication of KR20210056381A publication Critical patent/KR20210056381A/ko
Application granted granted Critical
Publication of KR102826491B1 publication Critical patent/KR102826491B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020217009936A 2018-09-04 2019-09-03 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드 Active KR102826491B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726562P 2018-09-04 2018-09-04
US62/726,562 2018-09-04
PCT/US2019/049276 WO2020051105A1 (en) 2018-09-04 2019-09-03 Dimethyl amino azetidine amides as jak inhibitors

Publications (2)

Publication Number Publication Date
KR20210056381A KR20210056381A (ko) 2021-05-18
KR102826491B1 true KR102826491B1 (ko) 2025-06-27

Family

ID=67982186

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217009936A Active KR102826491B1 (ko) 2018-09-04 2019-09-03 Jak 억제제로서 디메틸 아미노 아제티딘 아마이드

Country Status (27)

Country Link
US (4) US10947229B2 (https=)
EP (1) EP3837258B1 (https=)
JP (2) JP7324836B2 (https=)
KR (1) KR102826491B1 (https=)
CN (1) CN112739697B (https=)
AR (1) AR116115A1 (https=)
AU (1) AU2019336167B2 (https=)
BR (1) BR112021004052A2 (https=)
CL (1) CL2021000514A1 (https=)
CO (1) CO2021002977A2 (https=)
DK (1) DK3837258T3 (https=)
EA (1) EA202190681A1 (https=)
ES (1) ES2982858T3 (https=)
FI (1) FI3837258T3 (https=)
HR (1) HRP20241002T1 (https=)
HU (1) HUE068058T2 (https=)
IL (1) IL281146B2 (https=)
LT (1) LT3837258T (https=)
MA (1) MA53229A (https=)
MX (1) MX2021002521A (https=)
PH (1) PH12021550368A1 (https=)
PL (1) PL3837258T3 (https=)
PT (1) PT3837258T (https=)
SG (1) SG11202101734RA (https=)
SI (1) SI3837258T1 (https=)
TW (1) TWI791886B (https=)
WO (1) WO2020051105A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1252685A1 (zh) 2015-11-03 2019-05-31 Theravance Biopharma R&D Ip, Llc 用於治疗呼吸疾病的jak激酶抑制剂化合物
BR112019018648A2 (pt) 2017-03-09 2020-06-16 Theravance Biopharma R&D Ip, Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
PT3837258T (pt) 2018-09-04 2024-06-20 Theravance Biopharma R&D Ip Llc Amidas de dimetil amino azetidina como inibidores de jak
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
WO2020051139A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as jak inhibitors
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021226637A1 (en) * 2020-05-08 2021-11-11 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus with nezulcitinib
US20230021647A1 (en) * 2021-06-21 2023-01-26 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
JP7644873B2 (ja) * 2021-12-17 2025-03-12 デウン ファーマシューティカル カンパニー リミテッド （２Ｒ，３Ｓ）－２－（３－（４，５－ジクロロ－１Ｈ－ベンゾ［ｄ］イミダゾール－１－イル）プロピル）ピペリジン－３－オールの新規な酸付加塩および結晶形
US20250288561A1 (en) 2022-05-05 2025-09-18 Theravance Biopharma R&D Ip, Llc Nezulcitinib for delivery by nebulized oral inhalation
WO2023230236A1 (en) 2022-05-26 2023-11-30 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014567A1 (en) 2011-07-27 2013-01-31 Pfizer Limited Indazoles
WO2020181034A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
JP4836788B2 (ja) 2003-07-23 2011-12-14 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼ変調因子及びその使用法
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
EP2515655B1 (en) 2009-12-21 2015-08-05 Samumed, LLC 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof
MX368464B (es) 2013-12-05 2019-10-02 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
CR20160525A (es) 2014-05-14 2016-12-20 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
HK1252685A1 (zh) 2015-11-03 2019-05-31 Theravance Biopharma R&D Ip, Llc 用於治疗呼吸疾病的jak激酶抑制剂化合物
US10556901B2 (en) 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
US20180258546A1 (en) * 2017-03-09 2018-09-13 Lam Research Corporation Electroplating apparatus and methods utilizing independent control of impinging electrolyte
BR112019018648A2 (pt) 2017-03-09 2020-06-16 Theravance Biopharma R&D Ip, Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
US10406148B2 (en) 2017-05-01 2019-09-10 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
CN110603255B (zh) 2017-05-01 2023-02-10 施万生物制药研发Ip有限责任公司 Jak抑制剂化合物的结晶型式
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AU2019306651B2 (en) 2018-07-20 2025-03-20 Porifera, Inc. Osmosis modules having recirculation loops
PT3837258T (pt) 2018-09-04 2024-06-20 Theravance Biopharma R&D Ip Llc Amidas de dimetil amino azetidina como inibidores de jak
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
WO2020051139A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as jak inhibitors
MX2021004582A (es) 2018-10-29 2021-06-15 Theravance Biopharma R&D Ip Llc Compuesto 2-azabiciclo hexano inhibidor de jak.
FI3932919T3 (fi) 2019-02-25 2024-08-30 Henan Medinno Pharmaceutical Tech Co Ltd Jak-inhibiittoriyhdiste ja sen käyttö
CN112279848A (zh) 2019-07-25 2021-01-29 四川海思科制药有限公司 一种泛JAKs抑制剂及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2021226637A1 (en) 2020-05-08 2021-11-11 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus with nezulcitinib
WO2022178215A1 (en) 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
TW202304902A (zh) 2021-03-26 2023-02-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之二鹽酸鹽之結晶形式
US20230021647A1 (en) * 2021-06-21 2023-01-26 Theravance Biopharma R&D Ip, Llc Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014567A1 (en) 2011-07-27 2013-01-31 Pfizer Limited Indazoles
WO2020181034A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction

Also Published As

Publication number Publication date
HRP20241002T1 (hr) 2024-10-25
EP3837258B1 (en) 2024-04-24
IL281146B1 (en) 2023-08-01
MX2021002521A (es) 2021-04-28
CN112739697A (zh) 2021-04-30
US20210155620A1 (en) 2021-05-27
MA53229A (fr) 2022-05-11
AU2019336167A1 (en) 2021-03-11
JP7324836B2 (ja) 2023-08-10
US12398135B2 (en) 2025-08-26
WO2020051105A1 (en) 2020-03-12
CL2021000514A1 (es) 2021-07-23
LT3837258T (lt) 2024-05-27
PT3837258T (pt) 2024-06-20
IL281146A (en) 2021-04-29
TWI791886B (zh) 2023-02-11
BR112021004052A2 (pt) 2021-05-25
AR116115A1 (es) 2021-03-31
SI3837258T1 (sl) 2024-09-30
US10947229B2 (en) 2021-03-16
ES2982858T3 (es) 2024-10-17
US11634419B2 (en) 2023-04-25
AU2019336167B2 (en) 2024-08-29
SG11202101734RA (en) 2021-03-30
CO2021002977A2 (es) 2021-05-31
EA202190681A1 (ru) 2021-05-28
US20250034131A1 (en) 2025-01-30
US20200071323A1 (en) 2020-03-05
TW202024073A (zh) 2020-07-01
JP2021535177A (ja) 2021-12-16
IL281146B2 (en) 2023-12-01
PH12021550368A1 (en) 2022-03-28
HUE068058T2 (hu) 2024-12-28
PL3837258T3 (pl) 2024-09-16
DK3837258T3 (da) 2024-07-22
EP3837258A1 (en) 2021-06-23
FI3837258T3 (fi) 2024-05-27
JP2022172299A (ja) 2022-11-15
CN112739697B (zh) 2023-10-20
KR20210056381A (ko) 2021-05-18
US20230322774A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
KR102826491B1 (ko) Jak 억제제로서 디메틸 아미노 아제티딘 아마이드
KR102533646B1 (ko) 4-원 헤테로시클릭 아미드를 포함하는 jak 저해제
US11713315B2 (en) 5 to 7 membered heterocyclic amides as JAK inhibitors
CA3053853C (en) Dimethyl amino azetidine amides and 5 to 7 membered heterocyclic amides as jak inhibitors
EA040464B1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA040902B1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210402

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220822

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240705

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250325

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250624

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250625

End annual number: 3

Start annual number: 1

PG1601 Publication of registration